Inaktiver Wert

Andere Sprachen Hemispherx BioPharma, Inc Nyse

Aktien

US42366C1036

Schlusskurs Nyse Andere Börsenplätze
- ^USD	-

29.04.	AIM ImmunoTech sagt, dass die Sicherheitsbewertung der ersten Dosisstufe der Bauchspeicheldrüsenkrebsstudie abgeschlossen ist	MT
10.04.	AIM Immunotech gibt positive Top-Line-Zwischenberichtdaten aus der Studie zu Ampligen in Kombination mit Pembrolizumab zur Behandlung von rezidivierendem Eierstockkrebs bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®	06.05.
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	29.04.
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer	29.04.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	25.04.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	18.04.
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs	15.04.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	11.04.
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10.04.
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10.04.
Challenges To Advance Notice Bylaws Are Spiking	08.04.
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	02.04.
North American Morning Briefing : Stocks Seen -2-	02.04.
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference	28.03.
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast	26.03.
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	26.03.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	25.03.
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research	25.03.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	22.03.
AIM ImmunoTech Announces Release of the Next CEO Corner Segment	20.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hemispherx BioPharma, Inc Nyse

Aktien

US42366C1036

Andere Sprachen

Filter